Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367(6477).

Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020;30(6):507–19.

Article  PubMed  PubMed Central  Google Scholar 

Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Giglio A, Di Federico A, Nuvola G, Deiana C, Gelsomino F. The Landscape of Immunotherapy in Advanced NSCLC: driving beyond PD-1/PD-L1 inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, vaccines). Curr Oncol Rep. 2021;23(11):126.

Article  PubMed  PubMed Central  Google Scholar 

Sgambato A, Casaluce F, Sacco PC, Palazzolo G, Maione P, Rossi A, et al. Anti PD-1 and PDL-1 immunotherapy in the treatment of Advanced non- small cell Lung Cancer (NSCLC): a review on Toxicity Profile and its management. Curr Drug Saf. 2016;11(1):62–8.

Article  CAS  PubMed  Google Scholar 

Mathew M, Enzler T, Shu CA, Rizvi NA. Combining chemotherapy with PD-1 blockade in NSCLC. Pharmacol Ther. 2018;186:130–7.

Article  CAS  PubMed  Google Scholar 

Peters S, Kerr KM, Stahel R. PD-1 blockade in advanced NSCLC: a focus on pembrolizumab. Cancer Treat Rev. 2018;62:39–49.

Article  CAS  PubMed  Google Scholar 

Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, et al. Development of a Companion Diagnostic PD-L1 immunohistochemistry assay for Pembrolizumab Therapy in Non-small-cell Lung Cancer. Appl Immunohistochem Mol Morphology: AIMM. 2016;24(6):392–7.

Article  CAS  Google Scholar 

Hansen AR, Siu LL. PD-L1 testing in Cancer: challenges in Companion Diagnostic Development. JAMA Oncol. 2016;2(1):15–6.

Article  PubMed  Google Scholar 

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–65.

Article  CAS  PubMed  Google Scholar 

Maule JG, Clinton LK, Graf RP, Xiao J, Oxnard GR, Ross JS et al. Comparison of PD-L1 tumor cell expression with 22C3, 28 – 8, and SP142 IHC assays across multiple tumor types. J Immunother Cancer. 2022;10(10).

Batenchuk C, Albitar M, Zerba K, Sudarsanam S, Chizhevsky V, Jin C, et al. A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28 – 8 and 22C3 in lung cancer and other malignancies. J Clin Pathol. 2018;71(12):1078–83.

Article  CAS  PubMed  Google Scholar 

Tung N, Ricker C, Messersmith H, Balmana J, Domchek S, Stoffel EM et al. Selection of Germline Genetic Testing panels in patients with Cancer: ASCO Guideline. J Clin Oncology: Official J Am Soc Clin Oncol. 2024:JCO2400662.

Wu CC, Wang YA, Livingston JA, Zhang J, Futreal PA. Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association. Nat Commun. 2022;13(1):42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim KH, Kim HK, Kim HD, Kim CG, Lee H, Han JW, et al. PD-1 blockade-unresponsive human tumor-infiltrating CD8(+) T cells are marked by loss of CD28 expression and rescued by IL-15. Cell Mol Immunol. 2021;18(2):385–97.

Article  CAS  PubMed  Google Scholar 

Araujo BLV, Hansen M, Spanggaard I, Rohrberg K, Reker Hadrup S, Lassen U, et al. Immune Cell profiling of peripheral blood as signature for response during checkpoint inhibition Across Cancer types. Front Oncol. 2021;11:558248.

Article  Google Scholar 

Frigola J, Navarro A, Carbonell C, Callejo A, Iranzo P, Cedres S, et al. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. Mol Oncol. 2021;15(4):887–900.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pagadala M, Sears TJ, Wu VH, Perez-Guijarro E, Kim H, Castro A, et al. Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response. Nat Commun. 2023;14(1):2744.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sammut SJ, Crispin-Ortuzar M, Chin SF, Provenzano E, Bardwell HA, Ma W, et al. Multi-omic machine learning predictor of breast cancer therapy response. Nature. 2022;601(7894):623–9.

Article  CAS  PubMed  Google Scholar 

Santhanam B, Oikonomou P, Tavazoie S. Systematic assessment of prognostic molecular features across cancers. Cell Genomics. 2023;3(3):100262.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Banchereau R, Leng N, Zill O, Sokol E, Liu G, Pavlick D, et al. Molecular determinants of response to PD-L1 blockade across tumor types. Nat Commun. 2021;12(1):3969.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang X, Pan A, Jia S, Ideozu JE, Woods K, Murkowski K, et al. Cystic fibrosis plasma blunts the Immune response to bacterial infection. Am J Respir Cell Mol Biol. 2019;61(3):301–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang X, Moore CM, Harmacek LD, Domenico J, Rangaraj VR, Ideozu JE et al. CFTR-mediated monocyte/macrophage dysfunction revealed by cystic fibrosis proband-parent comparisons. JCI Insight. 2022;7(6).

Han RH, Zhang XT. AImmune: a new blood-based machine learning approach to improving immune profiling analysis on COVID-19 patients. medRxiv. 2021:2021.11.26.21266883.

Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu M, Liu X, Suo P, Gong Y, Qu B, Peng X, et al. The contribution of hereditary cancer-related germline mutations to lung cancer susceptibility. Translational lung cancer Res. 2020;9(3):646–58.

Article  CAS  Google Scholar 

Qing T, Mohsen H, Marczyk M, Ye Y, O’Meara T, Zhao H, et al. Germline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden. Nat Commun. 2020;11(1):2438.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng Y, Fang YC, Li J. PD-L1 expression levels on tumor cells affect their immunosuppressive activity. Oncol Lett. 2019;18(5):5399–407.

CAS  PubMed  PubMed Central  Google Scholar 

Wu J, Cheung YH, Huang W, Yin C, Fallon JT, Dimitrova N, et al. Gene expression profiles of peripheral blood mononuclear cells from patients with advanced non-small cell lung cancer treated with anti-PD-1 monoclonal antibodies. J Clin Oncol. 2019;37(15suppl):e14107–e.

Article  Google Scholar 

Castano J, Aranda S, Bueno C, Calero-Nieto FJ, Mejia-Ramirez E, Mosquera JL, et al. GATA2 promotes hematopoietic development and represses Cardiac differentiation of human mesoderm. Stem cell Rep. 2019;13(3):515–29.

Article  CAS  Google Scholar 

Pan T, Liu J, Xu S, Yu Q, Wang H, Sun H, et al. ANKRD22, a novel tumor microenvironment-induced mitochondrial protein promotes metabolic reprogramming of colorectal cancer cells. Theranostics. 2020;10(2):516–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qiu Y, Yang S, Pan T, Yu L, Liu J, Zhu Y, et al. ANKRD22 is involved in the progression of prostate cancer. Oncol Lett. 2019;18(4):4106–13.

CAS  PubMed  PubMed Central  Google Scholar 

Dong X, Yang H, Zhou X, Xie X, Yu D, Guo L, et al. LIM-Homeodomain transcription factor LHX4 is required for the differentiation of Retinal Rod Bipolar cells and OFF-Cone bipolar subtypes. Cell Rep. 2020;32(11):108144.